Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024

Rhea-AI Summary

Vivani Medical (NASDAQ: VANI), a biopharmaceutical company developing miniaturized, ultra long-acting drug implants, will present at the Emerging Growth Conference on September 25, 2024. The interactive online event will feature a company overview by President and CEO Adam Mendelsohn, Ph.D., followed by a potential Q&A session.

Investors, advisors, and analysts are invited to attend the presentation scheduled for 1:10 p.m. Eastern Time, lasting 30 minutes. Attendees can register via the provided link to participate and receive updates. Questions can be submitted in advance to Questions@EmergingGrowth.com.

An archived webcast will be available after the conference on EmergingGrowth.com and the Emerging Growth YouTube channel.

ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at the Emerging Growth Conference on September 25, 2024.

Vivani invites individual and institutional investors as well as advisors and analysts to attend its interactive presentation at the Emerging Growth Conference. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s President and CEO, Adam Mendelsohn, Ph.D. in real time. Dr. Mendelsohn will deliver a company overview and may subsequently open the floor to questions. Please submit questions in advance to Questions@EmergingGrowth.com.

Vivani will be presenting at 1:10 p.m. Eastern Time for 30 minutes.

Please register at the following link to attend the conference and receive any updates released in follow up to the Vivani presentation: https://goto.webcasts.com/starthere.jsp?ei=1677125&tp_key=64e020ccee&sti=vani

An archived webcast will be made available after the conference on EmergingGrowth.com and on the Emerging Growth YouTube channel, http://www.YouTube.com/EmergingGrowthConference.

About Vivani Medical, Inc.

Leveraging its proprietary NanoPortal^TM platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight management in obese and overweight individuals. The semaglutide implant has the added potential benefit of once-yearly administration. NPM-119 refers to the Company’s Type 2 Diabetes development program utilizing a six-month, subdermal exenatide implant. Both the NPM-115 and NPM-119 programs utilize exenatide based products with a higher-dose associated with the NPM-115 program for chronic weight management in obese or overweight patients. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables. Medication non-adherence occurs when patients do not take their medication as prescribed. This affects an alarming number of patients, approximately 50%, including those taking daily pills. Medication non-adherence, which contributes to more than $500 billion in annual avoidable healthcare costs and 125,000 potentially preventable deaths annually in the U.S. alone, is a primary and daunting reason obese or overweight patients, and patients taking type 2 diabetes or other chronic disease treatments, face significant challenges in achieving positive real-world effectiveness. While the current GLP-1 landscape includes over 50 new molecular entities under clinical stage development, Vivani remains confident that its highly differentiated portfolio of miniature long-acting GLP-1 implants have the potential to provide an attractive therapeutic option for patients, prescribers and payers.

About Cortigent, Inc.

Vivani’s wholly owned subsidiary, Cortigent, Inc. (“Cortigent”), is developing precision neurostimulation systems intended to help patients recover critical body functions. Investigational devices include Orion®, designed to provide artificial vision to people who are profoundly blind, and a new system intended to accelerate the recovery of arm and hand function in patients who are partially paralyzed due to stroke. Cortigent has developed, manufactured, and marketed an implantable visual prosthetic device, Argus II®, that delivered meaningful visual perception to blind individuals. Vivani continues to assess strategic options for advancing Cortigent’s pioneering technology.

Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” and other similar expressions that in this press release, including statements regarding Vivani’s business, products in development, including the therapeutic potential thereof, the planned development therefor, the initiation of the LIBERATE-1 trial and reporting of trial results, Vivani’s emerging development plans for NPM-115, NPM-139, or Vivani’s plans with respect to Cortigent and its proposed initial public offering, technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani’s products, including NPM-115 and NPM-119; delays and changes in the development of Vivani’s products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani’s development activities, including Vivani’s ability to commence clinical development of NPM-119; risks related to the initiation, enrollment and conduct of Vivani’s planned clinical trials and the results therefrom; Vivani’s history of losses and Vivani’s ability to access additional capital or otherwise fund Vivani’s business; market conditions and the ability of Cortigent to complete its initial public offering. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company’s most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission filed on March 26, 2024, as updated by the Company’s subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240923627071/en/

Company Contact:

Donald Dwyer

Chief Business Officer

info@vivani.com

(415) 506-8462



Investor Relations Contact:

Jami Taylor

Investor Relations Advisor

investors@vivani.com

(415) 506-8462



Media Contact:

Sean Leous

ICR Westwicke

sean.leous@westwicke.com

(646) 866-4012

Source: Vivani Medical, Inc.

FAQ

When is Vivani Medical (VANI) presenting at the Emerging Growth Conference?

Vivani Medical (VANI) is presenting at the Emerging Growth Conference on September 25, 2024, at 1:10 p.m. Eastern Time for 30 minutes.

Who will be presenting for Vivani Medical (VANI) at the Emerging Growth Conference?

Adam Mendelsohn, Ph.D., the President and CEO of Vivani Medical (VANI), will be presenting at the Emerging Growth Conference.

How can investors attend Vivani Medical's (VANI) presentation at the Emerging Growth Conference?

Investors can attend by registering through the provided link in the press release. The event will be held online, allowing for interactive participation.

Will there be a Q&A session during Vivani Medical's (VANI) presentation?

While not guaranteed, the press release suggests that Dr. Mendelsohn may open the floor to questions after the company overview. Questions can be submitted in advance to Questions@EmergingGrowth.com.

Where can I find the archived webcast of Vivani Medical's (VANI) presentation?

The archived webcast will be available after the conference on EmergingGrowth.com and the Emerging Growth YouTube channel.